NCT04238624View on ClinicalTrials.gov

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

June 20, 2026

Study Completion Date

June 20, 2026

Conditions
Anaplastic Thyroid CancerThyroid CancerBRAF Gene MutationBRAF Mutation-Related Tumors
Interventions
DRUG

Dabrafenib

Participants will receive dabrafenib 150 mg orally twice a day

DRUG

Trametinib

Participants will receive trametinib 2 mg orally once a day

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Biotech Hunter | Biotech Hunter